Skip to main content
Clinical Trials/ACTRN12612000375853
ACTRN12612000375853CompletedNot Applicable

A Single Dose Clinical Trial to Study the Safety, Tolerability, and Pharmacokinetics of Intravenous MK-8226 in Healthy Subjects

Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.0 sites42 target enrollmentStarted: April 2, 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
42

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment

Eligibility Criteria

Ages
18 Years to 50 Years (—)
Sex
All

Inclusion Criteria

  • Subject judged to be in good health based on medical history, physical examination, ECG, vital sign measurements and laboratory safety tests
  • -Non-smoker
  • -BMI <30kg/m2

Exclusion Criteria

  • -Mentally or legally incapacitated or having significant emotional problems or has a history of clinically significant psychiatric disorder
  • -History of any clinically significant diseases/disorders
  • -Creatinine Clearance <80mL/min
  • -History of neoplastic disease
  • -Pregnant, breast feeding or expecting to conceive
  • -Major surgery or blood donation within 4 weeks
  • -Consumes excessive amounts of alcohol or caffeine
  • -History of significant allergies
  • -Regular/recreational drug user
  • -Participated in another clinical study within 4 weeks
  • -Positive to Hepatitis B, C or HIV
  • -Recent history of serious infection/infection requiring systemic antibiotics
  • -Received a live virus vaccine within 4 weeks.

Investigators

Sponsor
Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.

Similar Trials